merck sharp & dohme p53 peptide patent PEPTIDES - skin-care-products-with-copper-peptides Dohme Merck Sharp & Dohme and the P53 Peptide Patent Landscape

memory-enhancing-peptides The intricate relationship between the p53 tumor suppressor protein and its regulators has been a focal point of extensive research and patenting activity, particularly by Merck Sharp & Dohme (MSD). This exploration delves into the merck sharp & dohme p53 peptide patent landscape, highlighting key innovations and the scientific underpinnings that drive these advancements. The search_keyword reveals a keen interest in the intellectual property surrounding p53-modulating peptides, a crucial area in the development of novel cancer therapies2天前—Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements..

At the heart of this research lies the p53 protein, often referred to as the "guardian of the genome." Its primary role is to prevent the formation of cancer cells by controlling cell division, repairing DNA, and initiating programmed cell death (apoptosis) when damage is irreparable. However, in many cancers, the p53 pathway is inactivated, often through the overactivity of its negative regulators, such as MDM2 and MDMX.... Merck Sharp & Dohme Corp.MACROCYCLES THAT INCREASE p53 ACTIVITYAND THE USES THEREOF. WO2013096150A1 * 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Consequently, a significant therapeutic strategy involves reactivating p53 by inhibiting these regulatorspeptide inhibitors for mediating stress responses.

Merck Sharp & Dohme, along with its associated entities like MSD and MERCK SHARP & DOHME, has been at the forefront of developing molecules that target this interaction. Their patent portfolio showcases a strong emphasis on peptides and peptidomimetics designed to disrupt the p53-MDM2/MDMX binding. For instance, patents like US20220267376A1 and US10967042B2 describe p53-based peptidomimetic macrocyclesNew Co-STAR Receptor Shows Promise Treating Cancers in .... These are not simple peptides but rather complex molecules engineered for enhanced stability and binding affinity.peptide inhibitors for mediating stress responses The objective is to create peptides capable of inhibiting cellular and immune stress responses by effectively sequestering MDM2 and MDMX away from p53, thereby restoring p53's tumor-suppressing functions.

The development of stabilized p53 peptides is another critical area.Oligonucleotide delivery: a patent review (2010-2013) ... US9527896B2, for example, details "stabilized alpha-helix of p53(SAH-p53) peptides" that exhibit high affinity for HDM2. This stabilization is crucial because natural p53 peptides can be prone to degradation.Further, provided herein arep53-based peptidomimetic macrocyclesthat can be used for treating diseases including but not limited to cancer and other ... By engineering these peptides, researchers aim to improve their pharmacokinetic properties and therapeutic efficacy. The patent literature frequently mentions MACROCYCLES THAT INCREASE p53 ACTIVITY and Merck Sharp & Dohme MACROCYCLES INCREASING P53 ACTIVITY, underscoring the company's focus on developing macrocyclic compounds that can effectively modulate the p53 pathwayThe anticancer agents of the invention can be antibodies, binding proteins, or siRNAs that modify a nuclear factor that controls mtEF4 transcription or bind to ....

Beyond direct inhibition of MDM2/MDMX, the patent landscape also reveals broader applications. Some patents allude to peptides that can inhibit cellular and immune stress responses, suggesting a wider therapeutic potential for these molecules. Furthermore, the mention of NATRIURETIC PEPTIDE RECEPTOR A AGONISTS in patents assigned to Merck Sharp & Dohme indicates diversification in their research, though the direct link to p53 peptide patents may be indirect, focusing on other therapeutic areas.Described herein are stably cross-linkedpeptidesrelated to a portion of humanp53(“p53peptidomimetic macrocycles”). These cross-linkedpeptidescontain ...

The scientific rationale behind these patents is firmly rooted in understanding protein-protein interactionsBindingDB PrimarySearch_ki. The p53 protein's N-terminal transactivation domain binds to MDM2, leading to p53 ubiquitination and subsequent degradation. MDMX can also bind to p53, further inhibiting its transcriptional activity. By developing peptide inhibitors or peptidomimetics, companies like Merck Sharp & Dohme aim to block these critical interactions.Assay Description:The inhibition ofp53-MDM2 andp53-MDM4 interactions is ...Merck Sharp & Dohme2044; Amgen 997; Novartis 667; Astex Therapeutics 564 ... This strategy is well-established in cancer research, with MDM2-p53 interaction inhibitors being a significant class of investigational drugs.Merck seeks patents on cancer treatments, medications for ...

The search intent behind "merck sharp & dohme p53 peptide patent" likely stems from researchers, patent attorneys, or pharmaceutical professionals seeking to understand the existing intellectual property in this field, identify potential collaborators, or assess the competitive landscape. The recurring mention of MSD and Merck reinforces the central role of this pharmaceutical giant in this specialized area of drug discovery.US10967042B2 - Peptidomimetic macrocycles The ongoing development and patenting of novel peptides and peptidomimetics targeting the p53 pathway by Merck Sharp & Dohme signal a continued commitment to advancing cancer therapeutics through innovative molecular design.